CreaGen’s BDC program has collections of novel natural product and natural product-like scaffolds. Many of these scaffolds are target relevant cores that are designed to produce small molecule IP. These low molecular weight compounds are ideal for fragment-based screening. These cores have been designed with multiple diversity points to facilitate rapid synthesis of analogs that will provide SAR information. The multiple diversity points can also be be utilized to improve the pharmacokinetic properties of the target molecules such as solubility, bioavailability, selectivity and potency. CreaGen currently has 100 scaffolds in its BDC collection and continues to add approximately 25 new scaffolds per quarter. Our partners will have immediate access to our collections on a non-exclusive basis to develop potential new starting points for research programs.